ReNerve (RNV.AX) Stock Price

ReNerve Price

CLOSED
0.09
​
Market closed

Revenue at ReNerve has contracted by 3.1% per year over the past 4 years to 510,357.00 AUD. For ReNerve, the net margin of -1,091.9% is down versus -304.0% a few years ago.

ReNerve stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReNerve business model & stock analysis

ReNerve Ltd is a AU-based company operating in Health Care Equipment & Supplies industry. ReNerve Limited is an Australia-based medical device company developing tissue-based products for peripheral nerve repair and replacement and other related soft tissue surgical procedures. The company is focused on developing products that accelerate tissue regeneration while preventing scarring and negative inflammatory responses. Its products include NervAlign Nerve Cuff, NervAlign Nerve Graft and NervAlign Bionic Nerve. NervAlign Nerve Cuff is a soft, compatible protective wrap used to protect repaired injured nerves. The product is being developed for the surgical repair of transected (cut) and damaged nerves. NervAlign nerve grafts offers surgeons the ability to repair damaged nerves (neurotmesis) without the need to harvest the sural nerve from the patient. The company is developing, NervAlign Bionic Nerve, a combination polymer technology and its nerve graft to produce a replacement nerve that contains shaped ionic polymers which would enable the stimulation of the distal end of a nerve injury.

Frequently asked questions about ReNerve

Converted at the current exchange rate, the ReNerve share trades at 0.05 EUR (0.09 AUD).

The revenue of ReNerve is 510,357.00 AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of ReNerve is -5.57 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ReNerve is currently -2.69. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ReNerve stock.

The price-to-sales ratio (P/S) of ReNerve is currently 29.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ReNerve stock.

The Eulerpool Quality Score for ReNerve is 3/10.

The ISIN of ReNerve is AU0000358616. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of ReNerve is RNV.AX. The ticker symbol is used to trade ReNerve shares on the stock exchange.

Fair ValueTerminal
0.07 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Nov 26, 2024
ISIN
AU0000358616
Cusip
Q80810106
Market capitalization
12.40 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
3.90
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-175.44 %
Last updated Oct 24, 2026, 12:37 PM

ReNerve Peer Group

All fundamentals and in-depth analysis of ReNerve

Our stock analysis for ReNerve stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReNerve. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.